bluebird bio, Inc (BLUE) saw its loss widen to $68.71 million, or $1.68 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $56.27 million, or $1.52 a share. Revenue during the quarter surged 355.77 percent to $6.83 million from $1.50 million in the previous year period.
Operating loss for the quarter was $69.91 million, compared with an operating loss of $57.38 million in the previous year period.
“In the first quarter of 2017, we have been laser-focused on continuing to develop our commercial and manufacturing infrastructure and ensuring that we are prepared for future MAA and BLA filings,” said Nick Leschly, chief executive officer bluebird. “Throughout 2017, we will be presenting data across all four of our clinical programs. On our two most advanced programs in TDT and cerebral adrenoleukodystrophy, these data will dictate the timing and path for future regulatory submissions in the US and Europe. For our Phase 1/2 programs in SCD and multiple myeloma, the 2017 data will dictate the timing and path for our planned Phase 3 trials. I’m enthusiastic about the progress our teams are making, and look forward to continuing to move our programs forward through the second half of 2017.”
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
